Baricitinib

Systematic (IUPAC) name

2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
Clinical data
Legal status	Investigational
Identifiers
CAS Registry Number	1187594-09-7
ATC code	None
PubChem	CID 44205240
ChemSpider	26373084
ChEMBL	CHEMBL2105759
PDB ligand ID	3JW (PDBe, RCSB PDB)
Chemical data
Formula	C₁₆H₁₇N₇O₂S
Molecular mass	371.42 g/mol
SMILES CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

Baricitinib (formerly INCB28050, LY3009104)^[1] is an oral JAK1 and JAK2 inhibitor.

Baricitinib is in Phase III development by Eli Lilly and Incyte as a potential treatment for rheumatoid arthritis.^[2] It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy. The related compound in JAK inhibitor is Tofacitinib, currently approved for the treatment of rheumatoid arthritis (RA) in the United States.

References

↑ "Baricitinib" (PDF). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.
↑ "Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Retrieved 2 Mar 2015.